Message From Wall Street: Cap Those Price Increases
This article was originally published in RPM Report
Executive Summary
With the Democrats in control of Congress and high drug prices still making headlines, some Wall Street analysts are suggesting a proactive, and surprising, response from Big Pharma: voluntary price caps.
You may also be interested in...
Payer Pressure Comes to Oncology
Why Payers Are Making Life Tougher for Oncology Marketers, and How Marketers Must Adapt.
Negotiating Price Negotiation: Why the Democrats Will Struggle to Pressure Part D Prices
The new Congress wants to make federal price negotiation under Medicare a reality. But it won't be easy. Big Pharma should expect plenty of interference from the Democrats in Part D, but it is hard to see a meaningful impact on prices in the near term.
Part D Pricing and Subpoena Power: What the November Elections Could Mean for Wall Street
The pharmaceutical industry has a lot riding on the mid-term elections: the Democrats only need to take back one chamber of Congress to do damage on Wall Street.